Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:25:24.515Z.
Calculation as of: 2026-10-06T21:25:24.515Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$5.70M
EV/Sales Ratio
N/A
TTM Avg
19.97x
3Y Avg
19.97x
5Y Avg
19.97x
Market Cap
$5.82M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.89M
EV/Sales Ratio
0.06x
TTM Avg
0.10x
3Y Avg
0.09x
5Y Avg
0.46x
Market Cap
$5.35M
EV/Sales Ratio
10.13x
TTM Avg
29.50x
3Y Avg
46.21x
5Y Avg
38.89x
Market Cap
$5.92M
EV/Sales Ratio
48.58x
TTM Avg
59.29x
3Y Avg
19360.66x
5Y Avg
791152.03x
Market Cap
$5.32M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.63M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A | 19.97x | 19.97x | 19.97x |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.83M | 1.00x | 0.52x | 1.80x | 5.65x |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | 0.06x | 0.10x | 0.09x | 0.46x |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | 10.13x | 29.50x | 46.21x | 38.89x |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | 48.58x | 59.29x | 19360.66x | 791152.03x |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A | 2.85x | 161.09x | 86.59x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
